Table 1.
Selected series for the comprehensive treatment of metastatic NSCLC.
| Study | N | Metastatic sites | Treatments | 1-year PFS | 5-year OS |
|---|---|---|---|---|---|
| University of Maryland [23] | 72 | Brain (metachronous) | SRS | 13.2% | |
| University of Maryland [24] | 42 | Brain (synchronous) | SRS, TS, RT, CRT, HIGRT | 21% | |
| Hopital Louis Pradel Hospices Civils de Lyon, Lyonnce [25] |
51 | Brain (synchronous) | BS, TS, RT, CRT | 42% (BS + others) versus 5% (BS only)* | |
| University of Rochester [26] | 38 | Multisite, 1–8 metastases | HIGRT | 14% | |
| Rush University Medical Center [27] | 23 | Multi-site, 1-2 metastases | TS, RT, HIGRT | 22% | |
| University of Chicago [28] | 25 | Multi-site, 1–5 metastases | HIGRT (3–10 fx) | 28% | 53% (18 mo) |
| Maastricht University Medical Center [29] | 39 | Brain, bone, adrenal | TS, SRS, RT, HIGRT | 24%* |
*2 yr estimates; SRS: stereotactic radiosurgery; BS: brain surgery; TS: thoracic Surgery; RT: radiotherapy; CRT: chemoradiotherapy; HIGRT: hypofractionated image-guided radiotherapy.